Navigation Links
DuPont Leader Overviews 2012 Seed Research Pipeline with Investors
Date:3/7/2012

NEW YORK, March 7, 2012 /PRNewswire/ -- Innovative technology, local product advancements and a strong 2012 research pipeline have positioned DuPont's seed business, Pioneer Hi-Bred, for continued growth, Pioneer President Paul E. Schickler told attendees at the Goldman Sachs Agricultural Biotech Forum today.

"Global trends like an expanding middle class and rapid urbanization in developing economies are driving the demand for food and require constant innovation, global science and local solutions to feeding a growing population," said Schickler.  "Pioneer is dedicated to meeting these challenges and building upon our double-digit sales growth in 2011 with the Right Product Right Acre strategy."

Schickler presented the 2012 seed research pipeline that features five product advancements and three program additions as a result of last year's R&D efforts.  With many advancing programs close to commercialization, Pioneer also received 39 regulatory approvals in 2011 and submitted another 34 documents pending approval.

This year's pipeline advancements underscore Pioneer's success with the Optimum® AcreMax® family with a wave of insect protection products launching commercially in 2012.  Together Optimum® AcreMax® 1 and Optimum® AcreMax® XTRA are anticipated to achieve 65 percent penetration of the company's above and below ground insect protection offering in North America.

"Our ability to innovate stems from our close relationships with growers as we look for new products and new ways to serve our customers," Schickler said.

Schickler used the Brazil soybean product evolution as an example of Pioneer's multi-pronged approach to product development.  Pioneer® brand Y series soybeans on the market today have been developed specifically for that country.  Using tools like the Accelerated Yi
'/>"/>

SOURCE DuPont
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
2. Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Childrens Health Care
3. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
4. DuPont and State of Delaware Unveil $80 Million Innovation Center Partnership
5. DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain
6. DuPont Opens Research & Development Center in India
7. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
8. DuPont Launches Innovative Renewably Sourced Material for Carpet Cushion
9. DuPont Takes Aggressive Actions to Strengthen Competitiveness and Increase Cash Flow
10. DuPont Unveils New Strategy to Expand its Seed Business
11. DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... VANCOUVER, March 31 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... announced it has completed an Amended and Restated ... International Inc. (Baxter). As consideration for the Amended ... receive $25 million. , Angiotech and Baxter initially ...
... AG (VSE: ICLL) today announced that it will host ... and Drug Administration,s (FDA) approval of IXIARO(R), a new ... initial target for use of Intercell,s vaccine - the ... - will be adult travelers and military personnel who ...
... 31 DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced its financial results for 2008. DOR,s revenues for ... in 2007. The increase was due primarily to ... resulting achievement of certain research and development milestones with ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 2Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 3Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc. 4Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 2Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... their mid-thirties and forties, face a devastating prognosis: ... decades. "Mutant" protein clusters, long blamed for the ... primary focus of therapies in development by pharmaceutical ... Gerardo Lederkremer and Dr. Julia Leitman of Tel ... in collaboration with Prof. Ulrich Hartl of the ...
(Date:4/23/2014)... NY. (Apr. 23, 2014) People who have had ... to restore neurological function. However, a study conducted in ... of Cell Transplantation , but is currently freely ... http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one group of ... (PBSCs) injected directly into the brain and a similar ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... Scientists at the Zucker Hillside Hospital campus of the ... markers that can increase a persons risk for schizophrenia. ... of the National Academy of Sciences, the research team ... be inherited in a recessive manner. A recessive trait ...
... have used ultraviolet light to sculpt three-dimensional microparticles ... and tissue engineering. For example, they could be ... molecules, such as DNA, or to release drugs ... control over the size, shape and texture of ...
... Journal of Lipid Research (Vol. 48, No. 12) ... Disease Increases Progression of Atherosclerosis, Breaking the Vicious Cycle ... Genetic Variants Affect Weight-Associated Cholesterol Metabolism ... alter how the body adjusts cholesterol metabolism in response ...
Cached Biology News:Feinstein researchers develop new genetic method and identify novel genes for schizophrenia 2MIT sculpts 3-D particles with light 2Story ideas from the Journal of Lipid Research 2Story ideas from the Journal of Lipid Research 3
Request Info...
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Biology Products: